Skip to content
buyWeak

Michael W. Dunne bought $35k of ITRM

director at Iterum Therapeutics plc. 25,000 shares at an average of $1.40, traded Dec 22, 2023, filed Dec 27, 2023.

Conviction score
32
Value
$35k
25,000 shares
Holdings after
113,754
+28% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $35k at market
    +6
  • Relative to holdings
    Holdings up 28%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    3 buys in 90 days
    +5
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001209191-23-059750, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 22, 2023POpen-market purchase
Ordinary Shares
+25,000$1.40$35k113,754Dec 27, 2023

Related signals

Other insiders at Iterum Therapeutics plc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$2,191
6,000 shares
+3%
18Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$11k
15,000 shares
+7%
23Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$18k
10,000 shares
+13%
35Weak
ITRMbuy 2
Iterum Therapeutics plc
Michael W. Dunne
director
$41k
20,000 shares
+34%
39Weak
ITRMbuy 2
Iterum Therapeutics plc
Corey N. Fishman
Chief Executive Officer
$16k
10,000 shares
+22%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael W. Dunne bought $35k of ITRM | InsiderTell